NASDAQ: ENTX · Life Sciences · 4 alerts · CIK 1638097
Share price
$3.02Close, Nov 16
Market cap
$526M
Shares outstanding
174.14MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Entera Bio Ltd. filings on SEC EDGAR ↗
Entera Bio Ltd. is a development-stage biopharmaceutical company focusing on oral peptide delivery, specifically product candidates EB613 for osteoporosis and EB612 for hypoparathyroidism. As of November 2, 2026, the company had 174,137,771 ordinary shares outstanding and continues to operate with a history of losses, relying on potential strategic partnerships and future capital raises to fund its clinical development programs.
Entera Bio reported financial results for the third quarter of 2026, highlighting preparations for its Phase 3 study of EB613 in osteoporosis with site activation expected in late 2026. The company significantly expanded its leadership team with several senior clinical appointments and new board members to support late-stage execution. Net loss for the quarter was $3.1 million, with a cash position of $11.4 million as of September 30, 2026.
Term
Q3 2026
“The third quarter of 2026 transitioned our expanding team into late-stage clinical execution mode. The opportunity to evaluate the safety and efficacy of EB613 as the first oral anabolic treatment for osteoporosis has generated excitement among clinical investigators and patients.”
Miranda Toledano, Chief Executive Officer of Entera
Entera Bio Ltd. appointed Dr. Juan Camilo Arjona Ferreira, currently the CMO of Organon & Co., as a Class II director effective December 1, 2026. Simultaneously, Haya Taitel notified the board of her resignation as a director, also effective December 1, 2026. Dr. Arjona Ferreira will participate in the company's standard non-employee director compensation program.
Entera Bio appointed Laura Hamill, a former executive at Gilead and Amgen, to its Board of Directors effective December 1, 2026. She replaces Yonatan Malca, who is stepping down from the Board after 16 years of service. Ms. Hamill will serve on the audit and corporate governance committees and participate in the company's standard non-employee director compensation plan.